Recent Finacing
Recent Raise
GlioCART is a University of Basel spin-off developing a dual-acting, genetically engineered cell therapy that targets both glioblastoma tumors and their immunosuppressive microenvironment.
Recent Investors
Total Raised
Funding round
Investor